Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lineage Cell Therapeutics (LCTX) Leases (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 10 years of Leases data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Leases fell 0.61% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 0.61%, while the annual FY2025 figure was $2.1 million, 0.61% down from the prior year.
  • Leases reached $2.1 million in Q4 2025 per LCTX's latest filing, down from $2.3 million in the prior quarter.
  • Across five years, Leases topped out at $3.2 million in Q1 2023 and bottomed at $22000.0 in Q2 2022.
  • Average Leases over 5 years is $1.9 million, with a median of $2.3 million recorded in 2025.
  • Peak YoY movement for Leases: crashed 99.12% in 2022, then soared 11382.14% in 2023.
  • A 5-year view of Leases shows it stood at $2.3 million in 2021, then tumbled by 94.8% to $121000.0 in 2022, then soared by 1984.3% to $2.5 million in 2023, then dropped by 14.99% to $2.1 million in 2024, then fell by 0.61% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $2.1 million in Q4 2025, $2.3 million in Q3 2025, and $1.8 million in Q2 2025.